ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will ...
5d
PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 22.9% during ...
Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...
But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should ORIC Pharmaceuticals ...
TipRanks on MSN16d
Oric Pharmaceuticals Expands Equity Incentive Plan for GrowthDiscover stocks' market position with detailed competitor analyses. Oric Pharmaceuticals ( (ORIC)) has provided an ...
In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback